Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.

Lung cancer (Amsterdam, Netherlands) - 1 Aug 2016

Chen Yu-Mu, Lai Chien-Hao, Rau Kun-Ming, Huang Cheng-Hua, Chang Huang-Chih, Chao Tung-Ying, Tseng Chia-Cheng, Fang Wen-Feng, Chen Yung-Che, Chung Yu-Hsiu, Wang Yi-Hsi, Su Mao-Chang, Huang Kuo-Tung, Liu Shih-Feng, Chen Hung-Chen, Chang Ya-Chun, Chang Yu-Ping, Wang Chin-Chou, Lin Meng-Chih

Abstract excerpt

OBJECTIVES: The clinical characteristics and survival of very young (≤40 years) and very old (>80years) patients with advanced non-small cell lung cancer (NSCLC) are distinct. However, the benefits of epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitors (TKIs) to patients at the extremes of age with NSCLC harboring EGFR mutation have not been well studied. We retrospectively studied the effect of...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Age Factors
Share to Carcinoma, Non-Small-Cell Lung

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to ErbB Receptors

Share to Molecular Targeted Therapy

Share to Neoplasm Metastasis

Share to Neoplasm Staging

Share to Protein Kinase Inhibitors

Share to Survival Analysis

Source

Identifiers

PMID: 27393514
DOI: 10.1016/j.lungcan.2016.05.020

Genes

EGFR

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Advanced non-Small cell lung cancer patients at the extremes of age in the era of epidermal growth factor receptor tyrosine kinase inhibitors.PMID 27393514Read ↗

Advanced non-small cell lung cancer in patients aged 45 years or younger: outcomes and prognostic factors.Semantic proximity Read ↗

Non-small cell lung cancer in the very young: Higher EGFR/ALK mutation proportion than the elder.Semantic proximity Read ↗

[Non-small cell lung cancer in adults under 40 years of age].Semantic proximity Read ↗

Characteristics of young lung cancer: Analysis of Taiwan's nationwide lung cancer registry focusing on epidermal growth factor receptor mutation and smoking status.Semantic proximity Read ↗

Treatment of Elderly Patients With Non-Small-Cell Lung Cancer: Results of an International Expert Panel Meeting of the Italian Association of Thoracic Oncology.Semantic proximity Read ↗

Recent advances in targeted advanced lung cancer therapy in the elderly.Semantic proximity Read ↗

[Trend analysis and clinicopathological characteristics of 198 young patients with advanced lung adenocarcinoma].Semantic proximity Read ↗

Lung Cancer Versus "Young Cancer": Is Non-Small Cell Lung Cancer in Young Patients a Different Entity?Semantic proximity Read ↗

Epidermal growth factor receptor tyrosine kinase inhibitors in elderly patients with non-small cell lung cancer.Semantic proximity Read ↗

Treatment outcomes in elderly with advanced-stage non-small cell lung cancer.Semantic proximity Read ↗

Lepidic, Papillary Components and EGFR Mutations are Frequent in Patients With Lung Adenocarcinoma Who are Over 75 Years Old.Semantic proximity Read ↗

Frequent genomic alterations and better prognosis among young patients with non-small-cell lung cancer aged 40 years or younger.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.